SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (20661)7/27/2006 11:06:28 PM
From: NeuroInvestment  Respond to of 52153
 
There is a fair amount of debate in the stroke community about NXY-059 and whether it makes much of a difference at all--but if they do hit the primary endpoint, the FDA will be pressed hard to add something to what is essentially an empty toolbox at present (tPA). My point was not that the data is strong--it isn't, it is marginal--but that the 25% market penetration estimate is nonsense. It will be, to oversimplify, either 0 or 50%.

Harry
NeuroInvestment


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News